Jul 28 2023 This Week in Cardiology

Antiarrhythmic drugs in patients with CAD, observational studies, GLP-1 agonists, and the subcutaneous ICD are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. AAD in Patients with CAD

- The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease

https://doi.org/10.1016/j.jacep.2022.12.021

- Three Questions for Evidence-Based Cardiac Electrophysiology

https://www.ahajournals.org/doi/full/10.1161/circoutcomes.110.957381

- The Cardiac Arrhythmia Suppression Trial (CAST) https://www.nejm.org/doi/full/10.1056/nejm198908103210608

II. GLP-1 Agonists

Tirzepatide Powers Weight Loss in Two More Pivotal Trials https://www.medscape.com/viewarticle/994889

Semaglutide Use Surges in US Adults With Type 2 Diabetes https://www.medscape.com/viewarticle/994873

- Tirzepatide Once Weekly for the Treatment of Obesity

https://www.nejm.org/doi/full/10.1056/NEJMoa2206038

- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

https://doi.org/10.1016/S0140-6736(23)01200-X

III. S-ICD

S-ICD Shows Virtues, Limits in 'Real World' Postmarket Study https://www.medscape.com/viewarticle/994851

- Postapproval Study of a Subcutaneous Implantable Cardioverter-Defibrillator System https://doi.org/10.1016/j.jacc.2023.05.034

- Subcutaneous or Transvenous Defibrillator Therapy https://www.nejm.org/doi/full/10.1056/NEJMoa1915932

- Letter to the Editor https://www.nejm.org/doi/full/10.1056/NEJMc2034917

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net